British researchers said that they may have discovered a new and more effective treatment for pancreatic cancer after promising early trial results of an experimental drug combination.

Researcher from the Cancer Research UK’s Cambridge Research Institute carried out the experiment on mice said that the chemotherapy agent gemcitabine with an experimental drug called MRK003 begins a chain of events that eventually kills cancer cells. They said that now patients are testing the treatment to see if it will work for them.

According to the medical experts, they found that the adding up of MRK003 to gemcitabine, a drug which is used normally in patients with pancreatic cancer increased the capability of gemcitabine to demolish tumors.

The lead author the study Professor David Tuveson said that they have found that why these drugs together start out a domino consequence of molecular activity to stop cell endurance processes and destroy pancreatic cancer cells.

The UK health authority reported that nearly 8,000 people in the country are diagnosed every year with pancreatic cancer and this disease is the UK’s fifth most common cause of cancer death, while the rate of survival from the disease are very low in relation to other cancers.

Doctors said that the time duration between diagnosis and death is usually very short less than six months.

UK Health authorities in its recent data showed that in England nearly 16 percent of the patients stay alive beyond 12 months after diagnosis.

Professor Duncan Jodrell of cancer therapeutics at University of Cambridge said that they are pleased that the results of their latest and the most important research are now being evaluated in a clinical trial, to test whether this might be a new cure approach for pancreatic cancer patients.

*************************************************************

The Views and Opinions expressed by the author are his or her opinions only and do not necessarily reflect those of this Web-Site or its agents, affiliates, officers, directors, staff, or contractors. The author at the time of this article did not own any shares or receive any consideration financial or otherwise from any company or person mentioned or referred to in the article.